Biopharmaceutical firm AstaZeneca has announced that it is teaming up with researchers at the non-profit Medicines for Malaria Venture in an effort to "identify novel candidate drugs for the treatment of malaria." The MMV team "will screen 500,000 compounds in AstraZeneca's unique library for activity against P. falciparum, the most lethal of malaria parasites," according to the drug company's statement.